INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 128 filers reported holding INOVIO PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,369 | +24.9% | 21,515 | +43.4% | 0.00% | – |
| Q2 2023 | $6,698 | -47.0% | 15,000 | -2.7% | 0.00% | – |
| Q1 2023 | $12,640 | -47.7% | 15,415 | -0.5% | 0.00% | -100.0% |
| Q4 2022 | $24,157 | -10.5% | 15,485 | +0.5% | 0.00% | 0.0% |
| Q3 2022 | $27,000 | 0.0% | 15,415 | -0.3% | 0.00% | 0.0% |
| Q2 2022 | $27,000 | -51.8% | 15,465 | -1.2% | 0.00% | 0.0% |
| Q1 2022 | $56,000 | -28.2% | 15,645 | +0.2% | 0.00% | -50.0% |
| Q4 2021 | $78,000 | -48.7% | 15,620 | -26.4% | 0.00% | -50.0% |
| Q3 2021 | $152,000 | -22.8% | 21,224 | 0.0% | 0.00% | -20.0% |
| Q2 2021 | $197,000 | +4.8% | 21,224 | +4.6% | 0.01% | 0.0% |
| Q1 2021 | $188,000 | +43.5% | 20,284 | +37.1% | 0.01% | +25.0% |
| Q4 2020 | $131,000 | -34.5% | 14,790 | +99.5% | 0.00% | -42.9% |
| Q2 2020 | $200,000 | +19900.0% | 7,415 | +3607.5% | 0.01% | – |
| Q4 2017 | $1,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |